Lymphomas | Clinical

Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL

July 01, 2021

Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.

FDA Approval Sought for Copanlisib Plus Rituximab in Relapsed iNHL

June 21, 2021

A supplemental new drug application has been submitted to the FDA seeking approval for the combination of copanlisib and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s Lymphoma and is outside of the FDA accelerated approved indication for the treatment of relapsed follicular lymphoma who have received at least 2 prior systemic therapies.